Search alternatives:
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
c largest » _ largest (Expand Search), c large (Expand Search)
ai large » a large (Expand Search), via large (Expand Search), _ large (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
i large » _ large (Expand Search), a large (Expand Search), via large (Expand Search)
largest decrease » largest decreases (Expand Search), larger decrease (Expand Search), marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
c largest » _ largest (Expand Search), c large (Expand Search)
ai large » a large (Expand Search), via large (Expand Search), _ large (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
i large » _ large (Expand Search), a large (Expand Search), via large (Expand Search)
-
61
Table3_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
62
Table6_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
63
Table2_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
64
Table5_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
65
-
66
-
67
-
68
-
69
-
70
Table_2_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf
Published 2021“…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …”
-
71
Table_1_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf
Published 2021“…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …”
-
72
-
73
For a random opinion vector y(0), on ER models with <i>n</i> = 100 and <i>ρ</i> ∈ (0,1].
Published 2021Subjects: -
74
Data_Sheet_1_Application of a nomogram model for the prediction of 90-day poor outcomes following mechanical thrombectomy in patients with acute anterior circulation large-vessel o...
Published 2024“…Moreover, five variables, namely, age (odds ratio [OR]: 1.049, 95% CI [1.016–1.083]; p = 0.003), glucose level (OR: 1.163, 95% CI [1.038–1.303]; p = 0.009), baseline National Institute of Health Stroke Scale (NIHSS) score (OR: 1.066, 95% CI [0.995–1.142]; p = 0.069), unsuccessful recanalization (defined as a TICI grade of 0 to 2a) (OR: 3.730, 95% CI [1.688–8.245]; p = 0.001), and early neurological deterioration (END, defined as an increase of ≥4 points between the baseline NIHSS score and the NIHSS score at 24 h after MT) (OR: 3.383, 95% CI [1.411–8.106]; p = 0.006), were included in the nomogram to predict the potential risk of poor outcomes at 90 days following MT in LVO patients, with a C-index of 0.763 (0.693–0.832) in the training set and 0.804 (0.719–0.889) in the validation set.…”
-
75
Data_Sheet_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.docx
Published 2020“…However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.</p>Methods<p>We investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). …”
-
76
Data_Sheet_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.docx
Published 2020“…However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.</p>Methods<p>We investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). …”
-
77
-
78
-
79
-
80